首页> 美国卫生研究院文献>Oncology Letters >Positive response of a primary malignant pericardial mesothelioma to pemetrexed plus cisplatin followed by pemetrexed maintenance chemotherapy: A case report
【2h】

Positive response of a primary malignant pericardial mesothelioma to pemetrexed plus cisplatin followed by pemetrexed maintenance chemotherapy: A case report

机译:原发性恶性心包间皮瘤对培美曲塞加顺铂继之以培美曲塞维持化疗的阳性反应:一例

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Primary malignant pericardial mesothelioma (PMPM) is a rare tumor with poor prognosis. Surgery is the treatment of choice, but numerous cases are inoperable. For the treatment of inoperable or metastatic cases, systemic chemotherapy is required. However, a standard chemotherapeutic regimen for the treatment of pericardial mesothelioma has not yet been established. Chemotherapy involving pemetrexed and cisplatin has been actively used in the treatment of pleural or peritoneal mesothelioma, and may be considered for the treatment of PMPM. The present study reports the case of a patient with PMPM with lung metastasis who demonstrated a positive response to treatment with pemetrexed and cisplatin followed by pemetrexed maintenance chemotherapy, leading to prolonged progression-free survival for 21 months.
机译:原发性恶性心包间皮瘤(PMPM)是一种预后较差的罕见肿瘤。手术是首选的治疗方法,但很多情况是无法手术的。对于无法手术或转移性病例的治疗,需要全身化疗。但是,尚未建立用于治疗心包间皮瘤的标准化疗方案。涉及培美曲塞和顺铂的化学疗法已被积极用于胸膜或腹膜间皮瘤的治疗,可能被考虑用于治疗PMPM。本研究报道了一例发生肺转移的PMPM患者,该患者对培美曲塞和顺铂联合培美曲塞维持化疗的治疗表现出积极的反应,从而延长了21个月的无进展生存期。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号